« Back

Patient Care

Faculty Members in the Division of Hematology and Oncology at UTMB provide comprehensive state-of-the-art multidisciplinary cancer care for all stages of cancer. This includes common cancers such as breast, prostate, lung and colon as well as blood cancers such as lymphomas and leukemia. Each of our oncology physicians is ABIM (American Board of Internal Medicine) certified in Medical Oncology. Our physicians are also actively involved in clinical research and conduct a myriad of clinical trials including those in conjunction with NIH sponsored groups such as RTOG (Radiation Therapy Oncology Group).

Typically our oncology physicians are sub-specialized, lead multidisciplinary tumor boards and discuss patient care to arrive at optimal treatment recommendations. Dr. Alperin and Dr. Jana also provide consultations for the entire spectrum of benign blood disorders including bleeding and clotting disorders, abnormal blood counts such as Anemia, Thrombocytopenia, leucocytosis, polycythemia, etc. as well as uncommon conditions such as amyloidosis and hemochromatosis.

UTMB has a long tradition of excellence in education and preparing physicians for practice. The Division of Hematology and Oncology trains fellows toward their careers and provides great opportunities for residents and medical students to learn more about oncology, hematology and clinical research in those areas.

Our Clinics

Specialty Care Center at Victory Lakes
Cancer Center
2240 Gulf Freeway South, Suite 2.110
League City, Texas
Phone: 832-505-1910
Fax: 281-309-0147

Specialty Care Center at Victory Lakes
Breast Health & Imaging Center
2240 Gulf Freeway South, Suite 2.110
League City, Texas
Phone: 832-505-1700
Fax: 281-309-0147

University Hospital Clinics
1005 Harborside Drive, 3rd Floor
Galveston, Texas
Phone: : 832-505-1910
Fax: 281-309-0147

Lung Studies

Protocol Title

Date Study Opened

# of Pts Enrolled
To Date

# of Pts Enrolled in
June 2014

Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients-Phase 2




CALGB 30610/RTOG 0538: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide
(PI: Swanson)




RTOG 0937: Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC) (PI: Swanson)




UTSW/CPRIT: Phase III Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status (PI: Swanson)




If you have any questions regarding the above clinical trials or would like a complete list of all our available trials, please contact our research staff below.



Contact Number



Lisa Hernandez Garcia

Sr. Clinical Research Coordinator



Nakia Watson

Clinical Research Coordinator




Jessica Robertson, CCRP

Clinical Research Coordinator





Primary Objectives

To develop a non-invasive approach for assessment of de novo 3MH production in cancer patients early in the course of the disease as a way of assessing which patients are at high risk for future development of skeletal muscle atrophy

Patient Population

  • Patients 18 or older with histological or cytological evidence of SCLC, NSCLC or gastrointestinal cancer
  • Patient reported weight loss of ≤10% of usual body weight in the last 6 months
  • Life expectancy of greater than 6 months based on the judgment of treating physician
  • Serum creatinine ≤1.5 times the upper limit of normal
  • Patients with the following are excluded from participation: malabsorption, intractable vomiting or gastrointestinal obstruction, congestive heart failure, edema or ascites, liver function test results that will preclude administration of prescribed therapy, pregnant, nursing, or, if of child-bearing age, unwilling to use contraceptives



Protocol No. RTOG 0538 (CALGB 30610)

Primary Objectives

To determine whether administering high dose thoracic radiotherapy, 70 Gy (2 Gy once-daily over 7 weeks) or 61.2 Gy (1.8 Gy once-daily for 16 days followed by 1.8 Gy twice-daily for 9 days), will improve median and 2-year survival compared with 45 Gy (1.5 Gy twice-daily over 3 weeks) in patients with limited stage small cell lung cancer.


Patient Population

  • Histologically or cytologically documented small cell lung cancer.
  • Limited stage disease that is restricted to one hemithorax with regional lymph node metastasis, including ipsilateral hilar, ipsilateral and contralateral mediasti-nal, and ipsilateral supraclavicular lymph nodes
  • Must have measurable disease, which includes lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 2 cm with conventional techniques or as ≥ 1 cm with spiral CT scan.
  • No prior radiotherapy or chemotherapy for SCLC.

NOTE: Patients may have received one and only one cycle of chemotherapy prior to enrolling on CALGB 30610, which must have included cisplatin and etoposide

  • No prior mediastinal or thoracic radiotherapy.
  • Must not have had complete surgical resection of disease.
  • ECOG Performance Status of 0-2.
  • Non-pregnant and non-nursing.

Protocol No. RTOG 0937

Primary Objectives

To determine the 1-year overall median survival rate in patients with ED-SCLC with the administration of PCI alone versus PCI with consolidation extracranial RT following platinumbased chemotherapy

Patient Population

Patients with extensive disease small cell lung cancer, excluding CNS metastases; patients must have had radiographic evidence of 1-4 extra-cranial metastatic lesions prior to platinum-based chemotherapy AND have had radiographic partial or complete response to chemotherapy in a minimum of one site of disease and no progression in any site.

Protocol No. UTSW/CPRIT

Primary Objectives

To compare the efficacy by overall survival of standard radiation versus accelerated, hypofractionated, image-guided conformal radiotherapy in treatment of stage II-III NSCLC in patients with poor performance status.


Patient Population

  • Stages II or III non-small cell lung cancer (NSCLC) that would benefit from local radiation therapy
  • Recurrent NSCLC after surgery non-small cell lung cancer that would benefit from local radiation therapy
  • Zubrod performance status of 2 or greater

-OR Zubrod performance status 0-1 and weight loss > 10%
-OR medically unable to tolerate or refusing standard combined modality therapy

  • Total (aggregate) gross tumor volume _ 500 cm3 (500 cc's or 0.5 Liters)
  • No prior radiotherapy to the chest or neck that would result in overlap of radiation therapy fields
  • No chemotherapy within one week prior to study registration
Site Managed by UTMB Information Design Services.